Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

NCT ID: NCT06950814

Last Updated: 2025-04-30

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-04-05
• Study Completion Date: 2025-05-05

Brief Summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Conditions

Sarcomatoid Carcinoma; Liver Cancer; Adjuvant Therapy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy

postoperative adjuvant therapy

Intervention Type: PROCEDURE

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy

No interventions assigned to this group

Interventions

postoperative adjuvant therapy

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. patients who underwent liver resection

2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion Criteria

1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;

2. patients diagnosed with other specific types of sarcomas;

3. patients with concurrent other malignancies during the course of PHSC;

4. patients who were lost to follow-up or lacked essential clinical data.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

West China Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jiwei Huang

Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

West China Hospital

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jiwei Huang Professor

Role: CONTACT

huangjiwei@wchscu.cn

+86 18980606725

Facility Contacts

Jiwei Huang Huang Professor

Role: primary

huangjiwei@wchscu.cn

+86 18980606725

Other Identifiers

JHuang20231

Identifier Type: -

Identifier Source: org_study_id